CTRI/2018/03/012284
Completed
未知
A double blinded, randomized, placebo controlled study to evaluate the efficacy of hair tonic on healthy human subjects. - NI
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ITC R D Centre
- Enrollment
- 82
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Female subjects falling under Grade 2 â?? Grade\-4 of hair loss severity grade
- •2\)Male subjects falling under Grade 2 to Grade 4 of hair loss severity grade
Exclusion Criteria
- •1\)Subjects who are undergoing hair growth treatment 3 months before screening into the study.
- •2\)Subjects who have scalp conditions such as folliculitis, seborrheoic psoriasis of scalp, seborrheoic dermatitis and lichen planopilaris at the time of screening.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Effects of perioperative Recombinant Human Erythropoietin administration on proinflammatory cascade following breast cancer surgery.Female subjects with breast cancer stage II/III undergoing a modified radical mastectomyCancer - BreastInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12610000813088niversity Hospital of Ioannina22
Active, not recruiting
Not Applicable
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleEUCTR2006-003067-31-LTETI Pharma GmbH230
Active, not recruiting
Not Applicable
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of patient’s skin lesions.MedDRA version: 8.1Level: LLTClassification code 10003641Term: Atopic eczemaEUCTR2006-003066-34-DEETI Pharma GmbH
Active, not recruiting
Not Applicable
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleRhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.MedDRA version: 8.1Level: LLTClassification code 10039083Term: RhinitisEUCTR2006-003067-31-DEETI Pharma GmbH230
Active, not recruiting
Not Applicable
A study of evaluate the efficacy and safety of investigational product Femildo(TM) in management of sexual dysfunction in womeCTRI/2019/01/016868ADSO Naturals Holdings BV24